Bioventus (BVS) filed a registration statement Friday for the potential sale of up to $200 million of securities from time to time.
The filing covers the sale of the company's class A common stock, preferred stock, debt securities, warrants and units.
The company said certain selling shareholders may offer up to 35 million class A common shares, and Bioventus won't receive any proceeds from the sale.
Shares of the company fell 1.3% in recent after-hours trading.
Price: 13.04, Change: -0.17, Percent Change: -1.29
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.